Pharsight

Onglyza generic

Onglyza is an anti-diabetic drug owned by Astrazeneca Ab. The active ingredient in Onglyza is saxagliptin hydrochloride. The drug received its first market authorization on 31st July, 2009.

When will Onglyza generic be available?

The generic version of Onglyza is expected to be released after 30 November, 2028. This is due to the expiration of the patent US7951400 titled 'Coated tablet formulation and method' on this date.

Onglyza uses

Onglyza is used to treat type II diabetes. It works by administering Saxagliptin either alone or in combination with other drugs like insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.

Onglyza patent expiration

Onglyza has two patents, of which one has already expired. The remaining patent (US7951400) is set to expire on 30 November, 2028, post which Onglyza generics could be available. Below are the details of the patent:

EPO Oppostions filed on Onglyza

Litigations filed on Onglyza

Onglyza dosage

Want to ask something?